Arcutis Biotherapeutics Files 8-K on Financials
Ticker: ARQT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Arcutis Biotherapeutics dropped an 8-K on Jan 12th detailing financials. Check it out.
AI Summary
Arcutis Biotherapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This 8-K filing provides investors with an update on Arcutis Biotherapeutics' financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial condition and results of operations, not indicating any immediate adverse events.
Key Players & Entities
- Arcutis Biotherapeutics, Inc. (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- January 13, 2025 (date) — Filing Date
- 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361 (address) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it reports on 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
What is the exact date of the financial information reported?
The earliest event reported is as of January 12, 2025.
When was this 8-K filing submitted to the SEC?
The filing was submitted on January 13, 2025.
What is the primary business of Arcutis Biotherapeutics, Inc. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Arcutis Biotherapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-13 07:33:31
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ARQT The Nasdaq Global Sele
Filing Documents
- arqt-20250112.htm (8-K) — 28KB
- pressreleaseex991pre-earni.htm (EX-99.1) — 18KB
- a1a82a.jpg (GRAPHIC) — 25KB
- 0001787306-25-000004.txt ( ) — 208KB
- arqt-20250112.xsd (EX-101.SCH) — 2KB
- arqt-20250112_lab.xml (EX-101.LAB) — 22KB
- arqt-20250112_pre.xml (EX-101.PRE) — 13KB
- arqt-20250112_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 12, 2025, Arcutis Biotherapeutics, Inc., (the "Company") issued a press release announcing the Company's preliminary unaudited fourth quarter and full year 2024 revenue. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release , dated Jan uary 1 2 , 202 5 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUTIS BIOTHERAPEUTICS, INC. Date: January 13, 2025 By: /s/ David Topper David Topper Chief Financial Officer